Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:DMAC NASDAQ:EPRX NASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.75+14.6%$2.51$0.40▼$5.48$40.76M0.27565,693 shs319,964 shsDMACDiaMedica Therapeutics$4.12-2.4%$4.05$3.19▼$6.82$180.97M1.25392,943 shs203,997 shsEPRXEupraxia Pharmaceuticals$5.30-1.8%$4.79$2.20▼$6.20$194.18M1.5111,620 shs4,758 shsGNFTGENFIT$3.82-2.9%$3.98$2.55▼$6.42$196.76M1.142,827 shs2,836 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+14.58%-8.64%-11.29%+161.90%+252.93%DMACDiaMedica Therapeutics-2.37%-18.42%+15.41%-2.60%+25.61%EPRXEupraxia Pharmaceuticals-1.78%-3.39%-3.03%+32.43%+86.76%GNFTGENFIT-0.52%-1.55%+0.26%-10.86%-9.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.5282 of 5 stars0.05.00.00.00.60.80.0DMACDiaMedica Therapeutics1.7417 of 5 stars3.50.00.00.03.31.70.0EPRXEupraxia Pharmaceuticals2.5642 of 5 stars3.62.00.00.02.60.00.6GNFTGENFIT1.7154 of 5 stars3.53.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ADMACDiaMedica Therapeutics 3.00Buy$10.75160.92% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00107.39% UpsideGNFTGENFIT 3.00Buy$13.00240.76% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, EPRX, GNFT, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$11.007/18/2025DMACDiaMedica TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $14.007/18/2025DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.007/18/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSpeculative Buy5/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K91.56N/AN/A$0.06 per share45.83DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AGNFTGENFIT$76.77M2.48$0.07 per share56.26$1.50 per share2.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.13N/A∞N/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$25.50M-$0.76N/AN/AN/AN/A-367.73%-112.23%8/6/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/ALatest ABVC, EPRX, GNFT, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025DMACDiaMedica Therapeutics-$0.18N/AN/AN/AN/AN/A8/6/2025N/AEPRXEupraxia Pharmaceuticals-$0.21N/AN/AN/AN/AN/A5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.220.22DMACDiaMedica TherapeuticsN/A8.028.02EPRXEupraxia PharmaceuticalsN/A11.1011.10GNFTGENFIT0.081.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%DMACDiaMedica Therapeutics10.12%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT2.24%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%DMACDiaMedica Therapeutics7.30%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million14.08 millionNot OptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableABVC, EPRX, GNFT, and DMAC HeadlinesRecent News About These CompaniesGENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Time to Sell?August 1 at 3:50 AM | marketbeat.comKepler Capital Maintained a Buy Rating on Genfit (GNFT)July 28, 2025 | msn.comGENFIT (NASDAQ:GNFT) Shares Up 0.7% - Time to Buy?July 10, 2025 | marketbeat.comGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - The Manila TimesJuly 9, 2025 | manilatimes.netMGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialJuly 8, 2025 | globenewswire.comGENFIT: June 17, 2025 Combined Shareholders Meeting ResultsJune 17, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports First Quarter 2025 Financial InformationMay 23, 2025 | finanznachrichten.deGENFIT Reports First Quarter 2025 Financial InformationMay 22, 2025 | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comGENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 15, 2025 | finanznachrichten.deGENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 14, 2025 | globenewswire.comGenfit: Iqirvo's Success Can't Outweigh ACLF Pipeline RisksMay 12, 2025 | seekingalpha.comGENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory DocumentsMay 7, 2025 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5, 2025 | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deGENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 24, 2025 | globenewswire.comGENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 20, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for WeekMarch 14, 2025 | msn.comRoyalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEsMarch 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, EPRX, GNFT, and DMAC Company DescriptionsABVC BioPharma NASDAQ:ABVC$2.75 +0.35 (+14.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.78 +0.04 (+1.27%) As of 08/1/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.DiaMedica Therapeutics NASDAQ:DMAC$4.12 -0.10 (-2.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.10 -0.02 (-0.49%) As of 08/1/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.30 -0.10 (-1.78%) Closing price 08/1/2025 03:50 PM EasternExtended Trading$5.58 +0.27 (+5.18%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.GENFIT NASDAQ:GNFT$3.82 -0.12 (-2.93%) As of 08/1/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
